article thumbnail

Anocca signs licensing deal for EmendoBio’s gene-editing tech

Pharmaceutical Technology

Anocca has entered a licensing agreement with EmendoBio for the use of the latter’s OMNI-A4 nuclease, a gene editing technology.

article thumbnail

Almirall licenses IL-21 antibody from Novo Nordisk

Pharmaceutical Technology

Almirall has signed a licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s IL21-hindering antibody NN-8828.

Licensing 241
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CRISPR drug licensing deals secure $21bn in top three therapy areas over five years

Pharmaceutical Technology

Licensing agreements for innovator drugs utilising clustered regularly interspaced short palindromic repeats (CRISPR) technologies saw oncology, immunology, and central nervous system as the top three therapy areas by total deal value with a combined $21bn over the past five years.

Licensing 130
article thumbnail

J&J jumps on ADC train, signs $1.7bn licensing deal with LegoChem

Pharmaceutical Technology

J&J has acquired a global license for South Korean LegoChem’s ADC for $100m upfront along with milestone-based payments and tiered royalties.

Licensing 245
article thumbnail

Specialised Therapeutics partners with Treeway to license ALS drug

Pharmaceutical Technology

Specialised Therapeutics has entered into a licensing agreement with Treeway for TW001, designed for treating amyotrophic lateral sclerosis.

Licensing 246
article thumbnail

Genezen to license CSL’s lentiviral vector production system

Pharmaceutical Technology

Contract development and manufacturing organisation Genezen has announced plans to license CSL’s Cytegrity lentivirus production system.

Licensing 130
article thumbnail

AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront

Pharmaceutical Technology

AbbVie will pay $48m in upfront costs and up to $665m in milestone payments to license OSE’s monoclonal antibody OSE-230.

Licensing 130